Debyani Chakravarty

66.4k total citations · 1 hit paper
35 papers, 1.9k citations indexed

About

Debyani Chakravarty is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Debyani Chakravarty has authored 35 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cancer Research, 14 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Debyani Chakravarty's work include Cancer Genomics and Diagnostics (22 papers), Genetic factors in colorectal cancer (7 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Debyani Chakravarty is often cited by papers focused on Cancer Genomics and Diagnostics (22 papers), Genetic factors in colorectal cancer (7 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Debyani Chakravarty collaborates with scholars based in United States, United Kingdom and Switzerland. Debyani Chakravarty's co-authors include David B. Solit, Alicia Pedraza, Nikolaus Schultz, Cameron Brennan, Usha N. Kasid, Tatsuya Ozawa, Margaret Leversha, Tom Mikkelsen, Imran Ahmad and Yuqiang Fang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Debyani Chakravarty

31 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

2018 391 citations Joaquı́n Mateo, Debyani Chakravarty et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Debyani Chakravarty

Since Specialization

Citations

This map shows the geographic impact of Debyani Chakravarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debyani Chakravarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debyani Chakravarty more than expected).

Fields of papers citing papers by Debyani Chakravarty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debyani Chakravarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debyani Chakravarty. The network helps show where Debyani Chakravarty may publish in the future.

Co-authorship network of co-authors of Debyani Chakravarty

This figure shows the co-authorship network connecting the top 25 collaborators of Debyani Chakravarty. A scholar is included among the top collaborators of Debyani Chakravarty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debyani Chakravarty. Debyani Chakravarty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	AI cancer driver mutation predictions are valid in real-world data 2025 ·Nature Communications ·Thinh Ngoc Tran, Chris Fong, Karl Pichotta, Anisha Luthra, Ronglai Shen, (unknown), Michele Waters, Susie Kim, Xiang Li, Ino de Bruijn, Gregory J. Riely, Michael F. Berger, Marc Ladanyi, Debyani Chakravarty, Nikolaus Schultz, Justin Jee	0
2	Precision Oncology: 2025 in Review 2025 ·Cancer Discovery ·(unknown), (unknown), Alexander Drilon, Debyani Chakravarty	0
3	Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies 2025 ·JAMA Oncology ·Kanika Arora, Sarah P. Suehnholz, Hongxin Zhang, Irina Ostrovnaya, Ritika Kundra, Subhiksha Nandakumar, Moriah H. Nissan, A. Rose Brannon, Chaitanya Bandlamudi, Marc Ladanyi, Alexander Drilon, Carol L. Brown, David B. Solit, Nikolaus Schultz, (unknown), Debyani Chakravarty	3
4	Precision Oncology: 2024 in Review 2024 ·Cancer Discovery ·(unknown), (unknown), Alexander Drilon, Debyani Chakravarty	3
5	Tracking the FDA precision oncology drug approval landscape in OncoKB. 2024 ·Journal of Clinical Oncology ·Sarah P. Suehnholz, Ritika Kundra, Hongxin Zhang, Moriah H. Nissan, (unknown), (unknown), Nicole Fernandez, Subhiksha Nandakumar, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Aijazuddin Syed, A. Rose Brannon, Ross L. Levine, Ahmet Doǧan, Alexander Drilon, David B. Solit, Nikolaus Schultz, Debyani Chakravarty	1
6	Abstract 1252: AI-derived predictions improve identification of real-world cancer driver mutations 2024 ·Cancer Research ·Thinh Ngoc Tran, Chris Fong, (unknown), Anisha Luthra, Ronglai Shen, Yuan Chen, Michele Waters, Susie Kim, Gregory J. Riely, Debyani Chakravarty, Nikolaus Schultz, Justin Jee	0
7	Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses. 2024 ·Journal of Clinical Oncology ·Catherine O’Connor, (unknown), (unknown), Henry Walch, Andrea Gazzo, (unknown), Fergus Keane, Joshua D. Schoenfeld, (unknown), Sarah P. Suehnholz, Debyani Chakravarty, Fiyinfolu Balogun, Anna M. Varghese, Kenneth H. Yu, David P. Kelsen, Alicia Latham, Britta Weigelt, Wungki Park, Zsofia K. Stadler, Eileen M. O’Reilly	3
8	Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications 2023 ·Cancer Discovery ·Britta Weigelt, Antonio Marra, Pier Selenica, Eric Rios‐Doria, Amir Momeni Boroujeni, Michael F. Berger, Kanika Arora, (unknown), Alexia Iasonos, Debyani Chakravarty, Nadeem R. Abu‐Rustum, Arnaud Da Cruz Paula, Kimberly Dessources, Lora H. Ellenson, Ying L. Liu, Carol Aghajanian, Carol L. Brown	19
9	Precision Oncology: 2023 in Review 2023 ·Cancer Discovery ·Yonina R. Murciano‐Goroff, Sarah P. Suehnholz, Alexander Drilon, Debyani Chakravarty	18
10	AKT mutant allele-specific activation dictates pharmacologic sensitivities 2022 ·Nature Communications ·Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, (unknown), Mark T.A. Donoghue, (unknown), Swati Patel, Sizhi Paul Gao, (unknown), Sarah Phillips, Tara E. Soumerai, Wassim Abida, David M. Hyman, Alison M. Schram, David B. Solit, Lillian M. Smyth, Barry S. Taylor	26
11	Precision Oncology: 2022 in Review 2022 ·Cancer Discovery ·Ezra Y. Rosen, Alexander Drilon, Debyani Chakravarty	6
12	Clinical cancer genomic profiling 2021 ·Nature Reviews Genetics ·Debyani Chakravarty, David B. Solit	104
13	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors 2020 ·Urology ·Douglas A. Mata, Soo‐Ryum Yang, Donna C. Ferguson, Ying Liu, Rohit Sharma, Jamal Benhamida, Hikmat Al‐Ahmadie, Debyani Chakravarty, David B. Solit, Satish K. Tickoo, Sounak Gupta, Maria E. Arcila, Marc Ladanyi, Darren R. Feldman, Victor E. Reuter, Chad Vanderbilt	7
14	Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations 2019 ·Clinical Cancer Research ·Yoshiyuki Suehara, Deepu Alex, Anita S. Bowman, Sumit Middha, Ahmet Zehir, Debyani Chakravarty, Lu Wang, George Jour, Khédoudja Nafa, Takuo Hayashi, Achim A. Jungbluth, Denise Frosina, Emily K. Slotkin, Neerav Shukla, Paul A. Meyers, John H. Healey, Meera Hameed, Marc Ladanyi	98
15	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) breakdown → 2018 ·Annals of Oncology ·Joaquı́n Mateo, Debyani Chakravarty, Rodrigo Dienstmann, S. Jezdic, Abel González-Pérez, Núria López-Bigas, Charlotte K.Y. Ng, Philippe L. Bédard, Giampaolo Tortora, J.-Y. Douillard, Eliezer M. Van Allen, Nikolaus Schultz, Charles Swanton, Fabrice André, Lajos Pusztai	391
16	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era 2017 ·Annals of Oncology ·Anna M. Varghese, Arshi Arora, Marinela Capanu, Niedzica Camacho, Helen Won, Ahmet Zehir, Jianjiong Gao, Debyani Chakravarty, Nikolaus Schultz, David S. Klimstra, Marc Ladanyi, David M. Hyman, David B. Solit, Michael F. Berger, Leonard B. Saltz	73
17	EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines 2017 ·Scientific Reports ·Debyani Chakravarty, Alicia Pedraza, Jesse Cotari, A.H. Liu, (unknown), (unknown), Jason T. Huse, Grégoire Altan‐Bonnet, Cameron Brennan	32
18	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation 2011 ·Journal of Clinical Investigation ·Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A. Knauf, Xiao-Hui Liao, Brian L. West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen, Pat Zanzonico, Steven M. Larson, Samuel Refetoff, Ronald Ghossein, James A. Fagin	286
19	Role of SCC-S2 in Experimental Metastasis and Modulation of VEGFR-2, MMP-1, and MMP-9 Expression 2006 ·Molecular Therapy ·Chuanbo Zhang, Debyani Chakravarty, (unknown), (unknown), Howard E. Boudreau, Deepak Kumar, Imran Ahmad, Usha N. Kasid	83
20	Sphingosine kinases: A novel family of lipid kinases 2002 ·Progress in nucleic acid research and molecular biology ·Hong Liu, Debyani Chakravarty, Michael Maceyka, Sheldon Milstien, Sarah Spiegel	136

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact